公开(公告)号：WO2008149353A3

公开(公告)日：2010-02-25

申请号：PCT/IL2008000756

申请日：2008-06-04

Applicant: UNIV BEN GURION ,  GAZIT AVIV ,  SLAVIN SHIMON ,  PRIEL ESTHER ,  YITZCHAK SARA

Inventor： GAZIT AVIV ,  SLAVIN SHIMON ,  PRIEL ESTHER ,  YITZCHAK SARA

IPC: A01N43/04

CPC classification number: C07C215/80 ,  A61K31/03 ,  A61K31/05 ,  A61K31/055 ,  A61K31/136 ,  A61K31/66 ,  A61K31/695 ,  C07C39/367 ,  C07C43/225 ,  C07C43/23 ,  C07C215/50 ,  C07D213/16 ,  C07D213/30 ,  C07D295/096 ,  C07D295/135 ,  C07F9/5022

Abstract: The present invention is directed to use of a series of compounds and compositions comprising the same for activating telomerase and treating diseases, disorders and/or conditions related thereto.

Abstract translation: 本发明涉及一系列化合物和包含其的组合物用于活化端粒酶和治疗与之相关的疾病，病症和/或病症的用途。

公开(公告)号：WO2009060457A1

公开(公告)日：2009-05-14

申请号：PCT/IL2008/001472

申请日：2008-11-09

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. ,  DAGAN, Arieh ,  SLAVIN, Shimon ,  GATT, Shimon ,  ZAHAVI, Jeremy

Inventor： DAGAN, Arieh ,  SLAVIN, Shimon ,  GATT, Shimon ,  ZAHAVI, Jeremy

IPC: C07C215/10 ,  A61P35/00 ,  A61P43/00

CPC classification number: C07C215/12 ,  A61K31/133 ,  A61K31/4745 ,  A61K31/513 ,  C07C215/10 ,  Y02A50/409 ,  Y02A50/411

Abstract: The present invention provides new ceramide analogs indicated as the compounds of formula (II). These novel analogs exhibit a significant anti cancerous effect and are therefore provided as a pharmaceutical composition for treating cell proliferative diseases, neurodegenerative disorders, metabolism-associated conditions, infectious diseases, and immune-related disorders. The invention further provides combined compositions and kits combining the novel ceramide analogs of formula (II) with an additional therapeutic agent.

Abstract translation: 本发明提供了新的表示为式（II）化合物的神经酰胺类似物。 这些新型类似物表现出显着的抗癌作用，因此作为治疗细胞增殖性疾病，神经变性疾病，代谢相关病症，感染性疾病和免疫相关疾病的药物组合物提供。 本发明还提供组合的组合物和试剂盒，其将式（II）的新型神经酰胺类似物与另外的治疗剂组合。

公开(公告)号：WO2007105210A2

公开(公告)日：2007-09-20

申请号：PCT/IL2007000319

申请日：2007-03-13

Applicant: HADASIT MED RES SERVICE ,  YISSUM RES DEV CO ,  WEISS LOLA ,  MEINER VARDIELLA ,  LEITERSDORF ERAN ,  SLAVIN SHIMON ,  MECHOULAM RAPHAEL ,  GALLILY RUTH ,  LOTAN CHAIM ,  DURST RONEN ,  PUGATSCH THEA

Inventor： WEISS LOLA ,  MEINER VARDIELLA ,  LEITERSDORF ERAN ,  SLAVIN SHIMON ,  MECHOULAM RAPHAEL ,  GALLILY RUTH ,  LOTAN CHAIM ,  DURST RONEN ,  PUGATSCH THEA

IPC: A61K31/35

CPC classification number: A61K31/352 ,  A61K31/35

Abstract: The present invention provides the use of a Cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment as well as for the prevention of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b); as well as pharmaceutical compositions and therapeutic methods for treating the above. A fundamental parameter may include blood/plasma lipid profile; atherosclerosis plaque load; size of heart scar; thickness of heart scar; and cardiac function in general. In accordance with a preferred embodiment the invention concerns treatment of heart scars as well as the preventing the formation of heart scars.

Abstract translation: 本发明提供大麻二醇（CBD）化合物用于制备用于治疗的药物组合物以及用于预防影响选自（a）心血管系统的血管系统的至少一个基本参数的用途; （b）外周血管系统; 或（c）（a）和（b）的组合; 以及用于治疗上述的药物组合物和治疗方法。 基本参数可以包括血液/血浆脂质分布; 动脉粥样硬化斑块负荷; 心脏瘢痕大小; 心脏瘢痕厚度; 和心脏功能一般。 根据优选实施方案，本发明涉及心脏瘢痕的治疗以及防止心脏瘢痕的形成。

公开(公告)号：WO1997006805A1

公开(公告)日：1997-02-27

申请号：PCT/US1996013210

申请日：1996-08-12

Applicant: DAVIDSON, Clifford, M. ,  AGRICULTURAL RESEARCH ORGANIZATION, MINISTRY OF AGRICULTURAL, STATE OF ISRAEL ,  HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD., KIRYAT HADASSAH ,  NAGLER, Aron ,  SLAVIN, Shimon ,  VLODAVSKY, Israel ,  PINES, Mark

Inventor： DAVIDSON, Clifford, M. ,  AGRICULTURAL RESEARCH ORGANIZATION, MINISTRY OF AGRICULTURAL, STATE OF ISRAEL ,  HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT COMPANY LTD., KIRYAT HADASSAH

IPC: A61K31/505

CPC classification number: A61K31/517

Abstract: The invention provides a composition for attenuating neovasculatization and treating human malignancies, including a pharmaceutically effective amount of a compound of formula (I), wherein R1 is a member of the group consisting of hydrogen, halogen, nitro, benzo, lower alkyl, phenyl and lower alkoxy; R2 is a member of the group consisting of hydroxy, acetoxy and lower alkoxy; and R3 is a member of the group consisting of hydrogen and lower alkenoxy-carbonyl; as active ingredient therein, in combination with a pharmaceutically acceptable carrier.

Abstract translation: 本发明提供了一种用于减轻新血管病变和治疗人类恶性肿瘤的组合物，包括药学有效量的式（I）化合物，其中R 1是氢，卤素，硝基，苯并，低级烷基，苯基和 低级烷氧基 R2是由羟基，乙酰氧基和低级烷氧基组成的组的成员; 并且R 3是由氢和低级链烯氧基 - 羰基组成的组的成员; 作为其中的活性成分与药学上可接受的载体组合。

公开(公告)号：WO2021255723A8

公开(公告)日：2021-12-23

申请号：PCT/IL2021/050713

申请日：2021-06-14

Applicant: SLAVIN, Shimon

Inventor： SLAVIN, Shimon

IPC: C07K16/28 ,  C07K16/30 ,  A61K39/395 ,  A61K47/68 ,  A61P35/00 ,  A61P35/04 ,  A61P37/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/5158 ,  A61K47/6849 ,  C07K14/55 ,  C07K16/2809 ,  C07K16/2818 ,  C07K16/2887 ,  C07K16/2896 ,  C07K2317/31 ,  C07K2317/54 ,  C07K2317/73

Abstract: Immunotherapeutic Monoclonal Antibody Complexes or Conjugates (IMAC) comprising readily accessible antibodies designed and approved for clinical use are provided using a one- step method that combines killing of existing cancer cells in parallel with induction of long-lasting anti- cancer vaccination. Methods for their use, alone or in combination with cancer killer cells including intentionally mismatched donor T cells, NK cells concomitantly with additional anti-cancer or immune activating agents, or activation of patient's own immune system for personalized treatment of cancer and elimination of undesirable non-malignant cells are also provided. In addition, treatment method based on IMAC can be applied for in vivo vaccination against cancer using an existing malignant lesion as internal anti-cancer vaccine by engagement of patient's antigen presenting cells for induction of long-lasting anti-cancer vaccination in situ against residual or recurrent disease.

公开(公告)号：WO2009034574A2

公开(公告)日：2009-03-19

申请号：PCT/IL2008/001215

申请日：2008-09-11

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER ,  VOLOVITZ, Ilan ,  EISENBACH, Lea ,  COHEN, Irun R. ,  RAM, Zvi ,  SLAVIN, Shimon

Inventor： VOLOVITZ, Ilan ,  EISENBACH, Lea ,  COHEN, Irun R. ,  RAM, Zvi ,  SLAVIN, Shimon

IPC: A61K39/00

CPC classification number: A61K39/0011 ,  A61K2039/5152

Abstract: A method of treating cancer in an immune-privileged site of a subject in need thereof is provided. The method comprises systemically administering to an area outside the immune-privileged site of the subject, a therapeutically effective amount of naive, viable cells of a tumor of the subject, the tumor being in the immune-privileged site so as to generate an immune response in the subject, thereby treating the cancer in the immune-privileged site of the subject.

Abstract translation: 提供了在有需要的受试者的免疫特异部位中治疗癌症的方法。 该方法包括系统地施用受试者的免疫特权部位之外的区域，治疗有效量的受试者肿瘤的天真，活的细胞，肿瘤位于免疫特异位点以产生免疫应答 从而治疗受试者的免疫特异部位的癌症。

公开(公告)号：WO2008149346A2

公开(公告)日：2008-12-11

申请号：PCT/IL2008/000748

申请日：2008-06-03

Applicant: BEN GURION UNIVERSITY OF THE NEGEV RESEARCH AND DEVELOPMENT AUTHORITY ,  PRIEL, Esther ,  YITZCHAK, Sara ,  GAZIT, Aviv ,  SLAVIN, Shimon

Inventor： PRIEL, Esther ,  YITZCHAK, Sara ,  GAZIT, Aviv ,  SLAVIN, Shimon

IPC: C12Q1/68

CPC classification number: C07C215/80 ,  A61K31/03 ,  A61K31/05 ,  A61K31/055 ,  A61K31/136 ,  A61K31/66 ,  A61K31/695 ,  C07C39/367 ,  C07C43/225 ,  C07C43/23 ,  C07C215/50 ,  C07D213/16 ,  C07D213/30 ,  C07D295/096 ,  C07D295/135 ,  C07F9/5022

Abstract: The present invention is directed to tri-phenyl compounds that enhance the amplification of a nucleic acid of interest in a polymerase chain reaction (PCR) assay, kits comprising the same and applications thereof.

Abstract translation: 本发明涉及在聚合酶链式反应（PCR）测定中增强目标核酸扩增的三苯基化合物，包含该核酸的试剂盒及其应用。

公开(公告)号：WO2007105210A3

公开(公告)日：2007-09-20

申请号：PCT/IL2007/000319

申请日：2007-03-13

Applicant: HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LIMITED ,  YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  WEISS, Lola ,  MEINER, Vardiella ,  LEITERSDORF, Eran ,  SLAVIN, Shimon ,  MECHOULAM, Raphael ,  GALLILY, Ruth ,  LOTAN, Chaim ,  DURST, Ronen ,  PUGATSCH, Thea

Inventor： WEISS, Lola ,  MEINER, Vardiella ,  LEITERSDORF, Eran ,  SLAVIN, Shimon ,  MECHOULAM, Raphael ,  GALLILY, Ruth ,  LOTAN, Chaim ,  DURST, Ronen ,  PUGATSCH, Thea

IPC: A61K31/35

Abstract: The present invention provides the use of a Cannabidiol (CBD) compound for the preparation of a pharmaceutical composition for treatment as well as for the prevention of at least one fundamental parameter affecting a vascular system selected from (a) the cardiovascular system; (b) the peripheral vascular system; or (c) a combination of (a) and (b); as well as pharmaceutical compositions and therapeutic methods for treating the above. A fundamental parameter may include blood/plasma lipid profile; atherosclerosis plaque load; size of heart scar; thickness of heart scar; and cardiac function in general. In accordance with a preferred embodiment the invention concerns treatment of heart scars as well as the preventing the formation of heart scars.

公开(公告)号：WO2005077348A1

公开(公告)日：2005-08-25

申请号：PCT/IL2005/000196

申请日：2005-02-16

Applicant: YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM ,  HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. ,  WEISS, Lola ,  ZEIRA, Michael ,  MECHOULAM, Raphael ,  SLAVIN, Shimon ,  GALLILY, Ruth

Inventor： WEISS, Lola ,  ZEIRA, Michael ,  MECHOULAM, Raphael ,  SLAVIN, Shimon ,  GALLILY, Ruth

IPC: A61K31/05

CPC classification number: A61K31/05 ,  A61K36/185

Abstract: Use of a cannabidiol for the manufacture of a medicament identified for the treatment or prevention of diabetes and/or insulitis.

Abstract translation: 使用大麻二醇来制造用于治疗或预防糖尿病和/或胰岛炎的药物。

公开(公告)号：WO9820932A3

公开(公告)日：1999-10-21

申请号：PCT/US9720946

申请日：1997-11-14

Applicant: BAXTER INT ,  HADASIT MED RES SERVICE ,  SLAVIN SHIMON

Inventor： SLAVIN SHIMON

IPC: A61K35/12 ,  A61K35/14 ,  A61K35/28 ,  A61K38/00 ,  A61P43/00 ,  C12N5/0783 ,  C12N5/0789 ,  A61N5/10

CPC classification number: C12N5/0636 ,  A61K35/17 ,  A61K35/28 ,  A61K38/00 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0647

Abstract: The present invention features methods for conditioning patients prior to allegeneic stem cell transplantation. A first method involves treating a patient with a lymphoablative regimen that retiains a functional population of the patient's hematopoietic stem cells. A second method involves treating a patient with a myeloablative regimen that, conversely, retains a functional population of the patient's T lymphocyte population. In both methods, the patient is administered a donor-derived stem cell preparation after the conditioning regime to induce host anti-donor unresponsiveness. The patient may also be administered allogeneic cell therapy. The invention also features a method of making a patient-specific allogeneic stem cell preparation.

Abstract translation: 本发明的特征在于在致死性干细胞移植之前调节患者的方法。 第一种方法包括用消融方案治疗患者的血液干细胞的功能群体。 第二种方法涉及用清髓性方案治疗患者，相反地，保留患者T淋巴细胞群体的功能群体。 在两种方法中，在调理方案之后，向患者施用供体来源的干细胞制剂以诱导宿主抗供体无反应性。 患者也可以给予同种异体细胞疗法。 本发明还具有制备患者特异性同种异体干细胞制备物的方法。